Precipio, Inc. (PRPO) Earnings Call Transcript & Summary
April 2, 2026
What were the key takeaways from Precipio, Inc.'s April 2, 2026 earnings call?
Precipio, Inc. reported its Q4 2025 and fiscal year 2025 results, highlighting a significant transition to a self-sustaining business with positive cash flow. The company achieved $24 million in revenue for FY 2025, a 30% increase year-over-year, driven by growth in the Pathology Services division. Gross margins improved to 45% from 41% in 2024. Management did not provide specific forward guidance but emphasized a focus on growth and execution in 2026, particularly in the Products division.
What topics did Precipio, Inc. cover?
- Revenue Growth: Precipio reported $24 million in revenue for FY 2025, a 30% increase year-over-year, primarily driven by the Pathology Services division. Management highlighted 'continued expansion' and 'strengthening demand' as key factors.
- Gross Margin Improvement: Gross margins improved from 41% in 2024 to 45% in 2025, attributed to higher case volumes and a favorable case mix. The Products division saw a Q4 gross margin leap to 90% due to concentrated production runs.
- Products Division Challenges: The Products division did not grow as expected due to customer operational fluctuations and a limited commercial team. Management has since strengthened the team, hiring a Chief Commercial Officer and two business development officers.
- Operational Leverage: Precipio emphasized operational leverage, noting that 'incremental revenue can be absorbed efficiently' due to a fixed cost structure, leading to improved margins and cash flow.
- Market Interaction: Increased engagement with investors in 2025, with over 50 unique interactions, contributed to a 300% share price appreciation. Management plans to continue this engagement in 2026.
What were Precipio, Inc.'s April 2, 2026 results?
- Revenue: $24 million (30% YoY increase)
- Gross Margin: 45% (vs 41% in 2024)
- Products Division Gross Margin: 90% in Q4 (vs 30% in Q3)
- Pathology Services Revenue Mix: 90% (Current weighting towards pathology services)
Precipio's transition to a self-sustaining business with positive cash flow marks a significant milestone. The focus on expanding the Products division and leveraging operational efficiencies presents a promising growth trajectory. However, execution risks remain, particularly in scaling the Products division. Investors should monitor the effectiveness of the new commercial team and the company's ability to convert its pipeline into revenue-generating customers.
Earnings Call Speaker Segments
Good afternoon, and thanks for being here on our shareholder call for the fourth quarter and full year of 2025. To everyone who sent in questions beforehand, I want to express my appreciation. We'll try our hardest to get to them while we're on the line. Before we get into the financial review, though — and for those shareholders who are fairly new to Precipio — I want to pause and think about how our work touches patients each day. For every diagnostic test we perform, there's a patient awaiting answers, frequently at one of the hardest points in their life. The testing we do assists physicians in figuring out which treatments make the most sense for patients fighting cancer, and those answers need to come back fast and be right. Today's conversation will center mostly on financial results and progress on operations, but we should keep in mind that these numbers, in the end, stand for something past dollars and cents. They stand for what we contribute toward helping patients and their families get through their fight with cancer. Let's now go to a review of how we performed in 2025. In 2025, we saw a financial and strategic inflection. When last year started, we laid out an important goal for Precipio: shift away from being a company that uses cash to become a self-sustaining business generating positive cash flow. I'm happy to say that during 2025, we reached that inflection point. Over the course of the year, we hit a number of other significant milestones as well: ongoing revenue growth, better gross margin and operational leverage, the exercise of all remaining financial warrants, which cleared away any related overhang, and finishing repayment of the Change Healthcare loan, which lets the company move toward a clean balance sheet. For a long time, like most emerging diagnostic companies, we had to run the business under the ever-present constraint of preserving capital and stretching our runway. That discipline turned our company into the highly efficient organization it is today, though it also meant lots of decisions were made with shorter-term capital preservation in mind. Now we're entering a new stage in the company's development. The discipline is still there, but increasingly we can put resources toward growth initiatives and creating long-term value. The company is shifting away from a primary focus on stabilization toward one more and more centered on growth and execution. Later in the call, we'll point out a few examples of that shift. Now let me get to our financial results for the year. In fiscal year 2025, Precipio brought in $24 million of revenue, which is a 30% rise year-over-year versus 2024. That pace of growth shows continued expansion mainly in our Pathology Services division, plus strengthening demand for our specialized cancer diagnostic services and molecular testing technologies. Just as important, this growth shows the operational leverage built into our business model. A big share of our cost structure — laboratory infrastructure, scientific personnel and operational systems — is already there as a fixed cost. So added revenue can be taken on efficiently without needing operation costs to rise proportionally. So that means a larger share of those dollars drops straight through to the bottom line. Put another way, as revenue climbs, margins improve and cash flow gets stronger. Throughout the year, this operational leverage has been a major factor behind the better financial results we've delivered. I'm happy with what we accomplished in 2025, but I want to stress that in our view, we've only just begun to unlock the complete financial upside this model can deliver. Let's start with Pathology Services, the division that keeps serving as the operational and financial core of the business. Over the course of the year, this division saw robust organic growth, fueled both by bringing on new customers and by higher testing volume from customers we already had. What's especially encouraging is that this growth came without needing any meaningful extra capital expenditures or additions to laboratory staffing. Our lab infrastructure is still running far under its ceiling, which means added case volume moves through the system smoothly and feeds straight into better margins and cash generation. On top of bringing in revenue, the Pathology division gives Precipio a distinct strategic edge when it comes to our Products division. Since we run a complete clinical laboratory, we enjoy direct access to patient samples as they arrive and a real-world testing setting; that lets us develop, validate and refine diagnostic products quickly and efficiently prior to bringing them to market. Very few diagnostic companies have this dual setup — the ability to run both a clinical laboratory and the product development platform under one roof. And in our view, this integrated model hands Precipio a substantial competitive advantage. Going forward, our goal for the division stays simple: keep growing organically while letting it act as a dependable cash-generating foundation for the company. Now let's move to the Products division, which in our view holds the company's biggest long-term opportunity. First, it's important to recognize that revenues in the Products division failed to grow as we had anticipated this year. There are a handful of reasons for that; on this call, I want to address 2 primary causes. To start, we ran into several customer operational fluctuations. We did bring on new customers during the year, but we also saw pauses from several other customers stemming from their internal factors, everything from machine downtime to lab tech maternity relief. That led to temporary revenue loss and subsequent fluctuations, which basically wiped out a portion of the growth from new customers. The bright side is that we took lessons from all of these situations, and we put in place additional business continuity measures aimed at reducing these fluctuations going forward. Take, for instance, as part of our process when onboarding a new customer today, we may set up at the customer's selection our lab as a backup testing facility to be used should the customer hit a temporary operational interruption. If that happens, our clinical laboratory then serves as the customer send-out lab. What that means is that whenever they go offline for whatever cause, samples are routed to our laboratory following what the customers have specified, and that assists in keeping patient testing going through those disruptions in service. Their clinicians receive uninterrupted, steady service — which matters to every lab at all times — and for us it means revenue keeps flowing without interruption. The second factor behind the absence of meaningful expansion was how thin our commercial group was; we had a single senior executive devoting a portion of their hours to selling the product, along with one additional junior sales representative. For the level of growth we were aiming at, that group was simply not enough. Yet as 2024 began, that was the most we could manage financially. That illustrates the company operating on defense. When our cash situation improved, though, the approach shifted into playing offense. Near the close of 2025, once we observed the business turning profitable, we put our attention on building up the project commercial team. Come January 2026, we brought on board a seasoned Chief Commercial Officer with deep industry experience, as well as 2 experienced business development officers working full time. So we moved from essentially 1 individual handling commercial growth for the product division to a committed, seasoned group of 3 full-time members.
The group's mandate covers direct selling and also building the distributor ties required to reach customers that are harder to get to. With this team in place, I have confidence we'll achieve substantial progress. That said, 2025 brought encouraging movement within this division. Several elements weighed on product revenues, among them the relapse and later comeback of certain customers to full operational volume, newly acquired customers, and organic growth from existing customers who widened their test menu by taking on additional HemeScreen and Bloodhound panels; we anticipate feeling the effect of each of those elements across 2026. One thing we keep noticing about our platform: once labs adopt our technology, they typically don't simply remain at that level — over time, they also expand their usage. In addition, we continued to strengthen our distributor relationships, which are a vital foundation for our long-term growth plan. By working through distribution partners, we'll eventually be able to reach many more labs than we ever could through direct sales alone, which gives us a more scalable way to broaden adoption of our technology. Most of you know that acquiring a new customer — a new laboratory customer in the diagnostics field — takes several steps, including validation studies, workflow integration, and IT and regulatory review. Those kinds of processes can occasionally resist once revenue starts coming in. All the same, a steadily expanding group of labs continues moving through onboarding, and every single one represents the possibility of significant recurring revenue after it completes full clinical expansion. Now let me spend a moment on margins. Our overall gross margin improved compared with the prior year, climbing from 41% in 2024 to 45% in 2025, driven largely by greater case volumes in Pathology Services, a case mix that shifted in a favorable direction toward higher-margin tests, and continued efficiency improvements in operations; over in the Products division, margins absorbed a short-term setback caused by strategic investments spread across the year, including a move into a bigger facility as well as extra manufacturing during Q3, which held gross margins at 30%. In Q4, though, we witnessed a jump to 90% gross margin for our products. I realize that figure seems surprising, particularly climbing from 30% the quarter before. Allow me to walk through this operationally for a moment. First, to recap, we historically sat consistently around 40% to 50% gross margins. Then in Q3 we fell to 30% owing to the extra expenses loaded into manufacturing costs; so given our covered production volume, I'd prefer to use the 50% margin figure as our baseline. Here's the reason Q4 margins fell to 90%. While planning production in Q4 2025 and looking ahead to Q1 2026, we foresaw 2 disruptions to our production schedule. Two things were behind this. One was reduced output because of the holidays at year-end and employees being away. The other was scheduled servicing of equipment in the first quarter of 2026, a period when our manufacturing equipment would be shut down for about two to four weeks. As a result, to ensure we had sufficient supply on hand for our customers, in addition to the runs already planned to fulfill fourth-quarter orders, we produced a much larger quantity of inventory to meet the demand we expected in Q1 2026. It's worth remembering that once these items are manufactured, the intent is for them to be sold to our product customers as well as utilized inside our own clinical lab. Since that manufacturing batch was larger and more tightly grouped, we wound up unintentionally reaching a significantly greater margin — 90%. Even though that number was abnormally high because of how the run was produced, it demonstrates the scalability of our product manufacturing and the kind of margin effect we can anticipate seeing in the Products division as we grow. With rising volumes, we anticipate the division will deliver the robust margin profile characteristic of thriving diagnostic product businesses. In addition to the financial results, 2025 delivered a number of notable operational and commercial milestones. Let me walk you through several of them. We carried on growing the HemeScreen and Bloodhound molecular platform. We put out a joint academic study with Memorial Sloan Kettering Cancer Center in New York — one of the country's top cancer centers — that was really exciting, and it showed the novel clinical value of our Bloodhound BCR-ABL product. At the AMP conference, the Association of Molecular Pathology, we presented a poster alongside Wayne State University that showcased the clinical value of our HemeScreen cytopenia panel. We improved how customers are onboarded, we increased our manufacturing capacity, and we made the company's financial position stronger by paying down debt; in our view, all of these milestones help build a business that's more scalable and more durable. Now turning to market interaction. During 2025, we also started engaging more with the public markets. Through 2024 and earlier, we stayed fairly quiet and didn't interact much with investors. Whenever someone from the investment community contacted us asking for a management call, our usual answer was a polite no, along with the explanation that direct conversations between management and investors weren't happening at that time. Things shifted, though, as our narrative took shape and results got better, so starting in 2025 we started answering those requests and talking with investors — through one-on-one sessions, and also at a range of public events and conferences. Across 2025, we logged over 50 distinct engagements involving investors, family offices, institutional funds and analysts. My view is that the 300% rise in our share price during 2025 came mostly from how the business and finances performed, though stronger dialogue with investors also played a part. We intend to keep that market outreach going in the year ahead. As we turn our attention to 2026, the priority is expansion of the products business; thanks to the new product sales team we've brought on, which is dedicated and experienced, plus the process improvements now in place, our efforts will center on speeding up adoption of HemeScreen and Bloodhound, turning the laboratories in our pipeline into customers that actively generate revenue, and growing the count of institutions that use our platform. Beyond that, we expect the pathology services segment to keep growing, generating more cash that will mostly be reinvested to expand the products side of the business. One example of an opportunity before us involves acute myeloid leukemia, or AML, testing — particularly because most hospital labs today still rely on shipping tests out to reference labs, and because the speed at which results return can have a direct and critical impact on patients' lives. Right now, the majority of hospital laboratories across the country aren't doing AML testing on site. Instead, they send specimens from patients out to reference labs elsewhere. For AML testing, those outside labs typically deliver findings back to the physician in seven to ten days. That's despite AML guidelines requiring results within five days. Since multiple targeted therapies correspond to specific mutations under examination, obtaining results immediately is a vital matter of life or death. The problem is a significant gap between what doctors and their patients are up against clinically and the diagnostic options available to handle the majority of those situations. We've spotted a gap where testing processes aren't giving doctors the support they need to make quick calls. By pulling together the power of both our pathology services group and our blood AML assay, we're launching a service that combines fast molecular testing—and when I say fast, I mean you get results the following day—with a full analysis arriving 5 days later.
We think there's more to it than that — this offering could set our platform even further apart and widen the opportunity on the services side while also bringing labs into contact with the products we sell. That's merely a single illustration of the top-tier service our technology makes possible. Once we roll this offering out, we'll share more specifics; we see substantial room to grow the Products division's share within a market we estimate at $500 million in annual addressable terms in the U.S. As we carry out that plan across the coming 3 to 5 years, we anticipate the company's revenue mix shifting away from where it sits now — roughly a 90 to 10 weighting toward pathology service — toward a mix that's more balanced between pathology services and products. To wrap up, there's still work in front of us, but we feel the foundation we've established is solid and what lies ahead for us is significant; in 2026, we'll concentrate on executing for growth, commercial momentum, gaining market share, and making sure our progress gets communicated clearly to the market. I want to express thanks to our employees, customers, partners and shareholders for standing behind us and trusting us. We're eager to bring you another update next quarter as we keep carrying out our strategy and creating long-term value for our shareholders. Thanks, and enjoy your evening.
This call is finished now. We appreciate your joining the presentation today. You are welcome to leave the line at this point.
For developers and AI pipelines
Programmatic access to Precipio, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.